These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 35278825)

  • 1. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
    Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
    ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Shih JY; Luo YH; Chang GC; Chang JW; Wang CC; Yang TY; Fang WT; Shau WY
    J Formos Med Assoc; 2024 Aug; 123(8):875-881. PubMed ID: 38195317
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
    Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
    Bauer TM; Shaw AT; Johnson ML; Navarro A; Gainor JF; Thurm H; Pithavala YK; Abbattista A; Peltz G; Felip E
    Target Oncol; 2020 Feb; 15(1):55-65. PubMed ID: 32060867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Lorlatinib or Crizotinib in Advanced
    Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
    N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
    Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
    Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorlatinib Versus Crizotinib in Patients With Advanced
    Solomon BJ; Liu G; Felip E; Mok TSK; Soo RA; Mazieres J; Shaw AT; de Marinis F; Goto Y; Wu YL; Kim DW; Martini JF; Messina R; Paolini J; Polli A; Thomaidou D; Toffalorio F; Bauer TM
    J Clin Oncol; 2024 Oct; 42(29):3400-3409. PubMed ID: 38819031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
    Rupp M; Fanton-Aita F; Snow S; Wheatley-Price P; Melosky B; Juergens RA; Chu Q; Blais N; Banerji S; Ng R; Khoudigian S; Sharma A; On PV; Liu G
    Curr Oncol; 2023 Jul; 30(7):6559-6574. PubMed ID: 37504341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
    Sun S; Pithavala YK; Martini JF; Chen J
    J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.